(Q39459195)

12 September 2017

title

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition (English)

1 reference

12 September 2017

5

Keith T Flaherty

1 reference

12 September 2017

6

Hensin Tsao

1 reference

12 September 2017

Zhenyu Ji

1

1 reference

12 September 2017

Ching Ni Njauw

series ordinal

2

1 reference

12 September 2017

Michael Taylor

series ordinal

3

1 reference

12 September 2017

Victor Neel

series ordinal

4

1 reference

12 September 2017

language of work or name

English

0 references

publication date

13 October 2011

1 reference

Journal of Investigative Dermatology

12 September 2017

published in

1 reference

12 September 2017

volume

132

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

356-364

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Germline p16 mutations in familial melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Molecular therapeutic approaches to melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

A cell cycle regulator potentially involved in genesis of many tumor types

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

https://api.crossref.org/works/10.1038%2FJID.2011.313

1 reference

7 January 2021

Amplification of CDK4 and MDM2 in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

A novel transforming gene in a human malignant melanoma cell line

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Contrasting effects of nutlin-3 on TRAIL- and docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Recurrent patterns of dual RB and p53 pathway inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2011.313

7 January 2021

Identifiers

DOI

10.1038/JID.2011.313

1 reference

12 September 2017

1 reference